Generalized Anxiety Disorder (GAD). MedDRA version: 9.1 Level: LLT Classification code 10002855 Term: Anxiety
Conditions
Interventions
Product Name: PD 0332334
Product Code: PD-0332334
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: PD 0332334
Current Sponsor code: PD 0332334
Concentration unit: mg milligram(s)
Concentration
Sponsors
PFIZER
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Diagnosis of GAD (Diagnostic and Statistical Manual-IV [DSM-IV], 300.02) as established by the clinician (psychiatrist or licensed clinical psychologist) who has interviewed the subject using all sources of data including the Mini International Neuropsychiatric Interview (MINI) for DSM-IV Axis I disorders and other clinical information. Subjects with specific phobia(s) (as defined in DSM-IV) or dysthymic disorder will be allowed in the study. 2. Subjects must have a HAM-A total score >/=20 at the screening (V1) and randomization (V2) visits. Subjects must also have a Covi Anxiety Scale score of >/=9 and a Raskin Depression Scale score =65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: 1. Subjects with evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, pancreatic, neurologic, active infections, immunological, or allergic disease (including drug allergies). 2. Any of the following current (within the past 6 months through the present) DSM-IV Axis I diagnoses: Major depressive disorder; Obsessive compulsive disorder; Panic disorder; Agoraphobia; Posttraumatic stress disorder; Anorexia; Bulimia; Caffeine-induced anxiety disorder; Alcohol or substance abuse or dependence unless in full remission for at least 6 months; Social anxiety disorder. 3. Any of the following past or current DSM-IV Axis I diagnoses: Schizophrenia; Psychotic disorder; Delirium, dementia, amnestic, and other clinically significant cognitive disorders; Bipolar or schizoaffective disorder; Cyclothymic disorder; Dissociative disorders. 4. Antisocial or borderline personality disorder. 5. Serious suicidal risk per the clinical investigator?s judgment. (Note: The Suicidality module of the MINI diagnostic interview and the C-SSRS should be used as aids to the assessment of suicidality, but do not replace overall clinical judgement in determination of suicidal risk). 6. Current use of psychotropic medications (ie, drugs normally prescribed for depression, mania, anxiety, insomnia, or psychosis) that cannot be discontinued 2 weeks prior to randomization. Fluoxetine is prohibited within 5 weeks of randomization. In the event of inadvertent administration of psychotropic medications during the 2 weeks prior to randomization, continued eligibility will be assessed on a case by case basis by the investigator and the medical monitor 7. Use of drugs, supplements, prescription or nonprescription, or food that have psychoactive properties. In the event of inadvertent use of such products during the 2 weeks prior to randomization, continued eligibility will be assessed on a case by case basis by the investigator and the medical monitor. In addition, following a discussion of the individual case between medical monitor and the investigator, the medical monitor may allow minimal anxiolytic medication (for example a benzodiazepine) use for subjects who experience significant anxiety during the final week of the study (Days 64-71). 8. Subjects who have been treated with monoamine oxidase inhibitors in the 14 days prior to the baseline visit. 9. Regular use of benzodiazepines during the 3 months prior to Screening (for at least 5 out of 7 days per week). 10. Subjects initiating formal psychotherapy within 3 month prior to screening who intend to continue formal psychotherapy during the study. This includes psychodynamic, cognitive, and interpersonal therapies. 11. Positive drug tests at Screening (V1) or Randomization (V2) visits for any of the following substances or classes of compounds: amphetamines, barbiturates, opiates, benzodiazepines, sedatives and hypnotics, cocaine, phencyclidine (PCP), cannabinoids, or other illegal or illicit drugs. An exception to the exclusion for a positive benzodiazepine, opiate, or sedative and hypnotic drug test at the Screening (V1) visit may be granted by the Pfizer medical monitor if written evidence of a valid, current prescription is presented. 12. Any condition possibly affecting drug absorption (eg, gastrectomy). 13. Subjects with a current seizure disorder. 14. Subjects wit
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: The primary objective in protocol A5361019 is to assess the efficacy of PD 0332334 in the treatment of GAD as measured by the change from Baseline in the HAM-A total score at Week 8 (primary endpoint) and to assess the safety and tolerability of PD 0332334 in subjects with GAD.;Secondary Objective: . To assess the effects of PD 0332334 on disability associated with GAD (as measured by the change from Baseline in the Sheehan Disability total score). To assess the time course of action of PD 0332334 on the symptoms of GAD (as measured by the change from baseline HAM-A) over the 8-week double-blind treatment period. To assess the effect of PD 0332334 on the somatic symptoms of GAD. To assess the effect of PD 0332334 on the psychic symptoms of GAD. To assess sustained response at Week 1 (based on the HAM-A total score) of PD 0332334 in the treatment of GAD. To assess the effect of PD 0332334 on patient reported symptoms of GAD To assess the effects of PD 0332334 on sleep problems in subjects with GAD. To assess the effect of PD 0332334 on depressive symptoms in subjects with GAD.;Primary end point(s): Change from Baseline in HAM-A total score at Week 8. | — |
Countries
Germany, Hungary, Italy
Outcome results
None listed